Regulatory Shifts Impacting Clinical Trials
The clinical trials landscape in Europe is undergoing significant transformation in 2025. A convergence of regulatory updates, digital harmonization, and policy realignments is shaping how biotech and health tech companies approach innovation, patient engagement, and market entry. These changes are not only improving trial transparency and efficiency but also redefining how emerging therapies make their […]
Where Health Innovation Meets Smart Investment
At Thrive Capital, we spotlight emerging opportunities at the intersection of healthcare innovation and long-term investment growth. Whether you’re exploring fast-evolving trends in neurology, seeking early access to emerging technologies, or evaluating data-backed insights on innovation leaders—this is your starting point. A New Era of Health-Focused Investment Healthcare is transforming driven by smarter research, faster […]
Top Neurology Innovators to Watch
In 2025, innovation in neurology-focused healthcare continues to gain momentum, driven by cutting-edge science, evolving regulatory frameworks, and growing investor confidence. As the sector experiences accelerated breakthroughs and growing demand for advanced care solutions, a new generation of companies is stepping up with forward-looking platforms, technologies, and product pipelines. This analysis highlights ten companies making […]
Trade Report: Top 10 Neurology Innovators in 2025
As cannabinoid-based pharmaceuticals move from fringe therapy to mainstream treatment, a new class of biopharmaceutical innovators is capturing attention from regulators, clinicians, and investors alike. From neurological disorders like refractory epilepsy to inflammation and pain management, cannabis-derived therapies especially redefining global markets. This report provides a comparative analysis of 10 leading companies in the cannabis pharmaceutical […]
Cannabis and Epilepsy: Scientific Evidence, Clinical Trials, and Market Impact of High-CBD Therapies
Cannabis-based medicine has entered the scientific and regulatory mainstream, with epilepsy at the forefront of its therapeutic promise. High-CBD, low-THC cannabis formulations are now recognized as legitimate, evidence-backed options for patients with treatment-resistant epilepsy. This report dives into the clinical validation of these therapies, major product milestones such as Epidiolex, and the global regulatory and […]
The Rise of Decentralized Clinical Trials: What It Means for Innovation
Clinical trials have long been the engine of medical innovation — but they have also been notoriously slow, expensive, and exclusive. Now, decentralized clinical trials (DCTs) are emerging as a transformative solution, reshaping how research is conducted and who gets to participate.Driven by technological advances and accelerated by the COVID-19 pandemic, DCTs are unlocking faster, […]
Clinical Trial Success Rates: How Data Is Changing the Game
Clinical trials have always been the heartbeat of medical innovation—but they’re also notoriously risky, expensive, and time-consuming. For decades, investors, researchers, and pharmaceutical companies have operated under the sobering reality that most clinical trials fail. In fact, only around 9–14% of drugs that enter Phase I ever make it to market. But 2025 marks a […]